Janux Therapeutics (JANX)
JANX · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Immuno-Oncologysrc
Signal Snapshot
5
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
4 Phase 1
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- [(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. — Lancet (2026) PMID 42561994
- Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). — J Clin Oncol (2026) PMID 42507969
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Janux Therapeutics.
Full JANX Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.